Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy.

Ye Won Jeon Seung Taek Lim Hongki Gwak Seon Young Park Juhee Shin Hye Sug Han Young Jin Suh

Published in: Annals of surgical treatment and research (2021)

The use of pegfilgrastim prophylaxis during adjuvant TC chemotherapy is associated with significant decreases in the incidence of neutropenic events, hospitalization, and hospital care cost compared to those seen in patients without prophylaxis.

Keyphrases

locally advanced
healthcare
end stage renal disease
early stage
ejection fraction
chemotherapy induced
newly diagnosed
chronic kidney disease
low dose
prognostic factors
palliative care
high dose
emergency department
peripheral blood
radiation therapy
quality improvement
patient reported outcomes
acute care